A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729
This study is recruiting at 12 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- October 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- CBCC Global Research, Inc. ( Site 0123) · Bakersfield, CA
- Beverly Hills Cancer Center ( Site 0116) · Beverly Hills, CA
Connecticut · 1
- Stamford Hospital ( Site 0136) · Stamford, CT
Illinois · 1
- Orchard Healthcare Research Inc. ( Site 0115) · Skokie, IL
Missouri · 2
- Truman Medical Center ( Site 0126) · Kansas City, MO
- Cox Medical Center North ( Site 0133) · Springfield, MO
Montana · 1
- St. Vincent Frontier Cancer Center-Research ( Site 0105) · Billings, MT
New York · 1
- New York Oncology Hematology, P.C. ( Site 0132) · Albany, NY
Ohio · 1
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103) · Cincinnati, OH
Pennsylvania · 1
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134) · Lancaster, PA
Texas · 1
- Oncology Consultants P.A. ( Site 0113) · Houston, TX
Wisconsin · 1
- Circuit Clinical/SSM Health Dean Medical Group ( Site 0129) · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.